Corcept Therapeutics Incorporated (CORT - Free Report) announced that it has enrolled the first patient in a phase III study evaluating relacorilant in combination with Celgene’s [now part of Bristol Myers (BMY - Free Report) ] Abraxane (nab-paclitaxel) for the treatment of patients with metastatic pancreatic cancer.
The phase III study entitled RELIANT is expected to enroll 80 patients with metastatic pancreatic cancer in the United States. The primary endpoint of the study is to see the objective response rate while the secondary endpoints include progression-free survival and duration of response.
Both the FDA and the European Commission granted relacorilant an orphan drug designation for treating pancreatic cancer.
Shares of Corcept have rallied 39% so far this year against the industry’s decline of 7.3%.
We remind investors that Corcept’s lead candidate relacorilant is being evaluated in the phase III GRACE study to treat Cushing’s syndrome. Dosing is currently underway in the study at sites across the United States, Israel and Europe. The company plans to submit a new drug application for relacorilant in the second quarter of 2022. Both the FDA and the EMA designated relacorilant with an Orphan Drug tag for the treatment of Cushing’s syndrome.
Corcept plans to start a phase III study, GRADIENT, on relacorilant later in 2020 in patients whose Cushing’s syndrome is caused by adrenal adenoma.
Meanwhile, Corcept’s phase II study on relacorilant plus Abraxane to treat metastatic ovarian cancer is actively enrolling patients at sites in the United States and Europe, and is on track to produce results in first-half 2021.
The company also expects to begin a phase Ib study in the third quarter of 2020 on relacorilant plus Merck’s (MRK - Free Report) PD-1 checkpoint inhibitor, Keytruda (pembrolizumab), to treat patients with metastatic or unresectable adrenal cancer.
Zacks Rank and Key Pick
Corcept currently has a Zacks Rank #3 (Hold). A better-ranked stock in the same sector is BioLineRx Ltd. , which sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
BioLineRx’s loss per share estimates have been narrowed 19.1% for 2020 and 4.3% for 2021 over the past 60 days.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
See 8 breakthrough stocks now>>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Corcept Therapeutics Incorporated (CORT - Free Report) announced that it has enrolled the first patient in a phase III study evaluating relacorilant in combination with Celgene’s [now part of Bristol Myers (BMY - Free Report) ] Abraxane (nab-paclitaxel) for the treatment of patients with metastatic pancreatic cancer.
The phase III study entitled RELIANT is expected to enroll 80 patients with metastatic pancreatic cancer in the United States. The primary endpoint of the study is to see the objective response rate while the secondary endpoints include progression-free survival and duration of response.
Both the FDA and the European Commission granted relacorilant an orphan drug designation for treating pancreatic cancer.
Shares of Corcept have rallied 39% so far this year against the industry’s decline of 7.3%.
We remind investors that Corcept’s lead candidate relacorilant is being evaluated in the phase III GRACE study to treat Cushing’s syndrome. Dosing is currently underway in the study at sites across the United States, Israel and Europe. The company plans to submit a new drug application for relacorilant in the second quarter of 2022. Both the FDA and the EMA designated relacorilant with an Orphan Drug tag for the treatment of Cushing’s syndrome.
Corcept plans to start a phase III study, GRADIENT, on relacorilant later in 2020 in patients whose Cushing’s syndrome is caused by adrenal adenoma.
Meanwhile, Corcept’s phase II study on relacorilant plus Abraxane to treat metastatic ovarian cancer is actively enrolling patients at sites in the United States and Europe, and is on track to produce results in first-half 2021.
The company also expects to begin a phase Ib study in the third quarter of 2020 on relacorilant plus Merck’s (MRK - Free Report) PD-1 checkpoint inhibitor, Keytruda (pembrolizumab), to treat patients with metastatic or unresectable adrenal cancer.
Zacks Rank and Key Pick
Corcept currently has a Zacks Rank #3 (Hold). A better-ranked stock in the same sector is BioLineRx Ltd. , which sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
BioLineRx’s loss per share estimates have been narrowed 19.1% for 2020 and 4.3% for 2021 over the past 60 days.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
See 8 breakthrough stocks now>>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on BMY - FREE
Get the latest research report on MRK - FREE
Get the latest research report on CORT - FREE
Get the latest research report on BLRX - FREE